---
title: Colorectal Cancer Screening in Xinxiang City
nct_id: NCT06785714
overall_status: COMPLETED
sponsor: The First Affiliated Hospital of Xinxiang Medical College
study_type: OBSERVATIONAL
primary_condition: Colorectal Cancer
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06785714.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06785714"
ct_last_update_post_date: 2025-01-21
last_seen_at: "2026-05-12T07:27:04.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Colorectal Cancer Screening in Xinxiang City

**NCT ID:** [NCT06785714](https://clinicaltrials.gov/study/NCT06785714)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 25000
- **Lead Sponsor:** The First Affiliated Hospital of Xinxiang Medical College
- **Collaborators:** Xinxiang Municipal Health Commission, Xinxiang Center for Disease Control and Prevention, Xinxiang Central Hospital, The Affiliated People's Hospital of Xinxiang Medical University, The Third Affiliated Hospital of Xinxiang Medical College, Shanghai Jiao Tong University School of Medicine
- **Conditions:** Colorectal Cancer
- **Start Date:** 2024-09-01
- **Completion Date:** 2025-01-15
- **CT.gov Last Update:** 2025-01-21

## Brief Summary

The primary objective of this study is to evaluate the sensitivity of the fecal protein dual-index test reagent for the detection of colorectal cancer (CRC).

## Detailed Description

The project uses fecal hemoglobin and transferrin dual-index combined with reagents that can be self-tested at home (referred to as fecal protein dual-index detection reagents), combined with colorectal cancer risk factor questionnaires, to carry out colorectal cancer screening in people of specific ages in the city, aiming to achieve early screening, early diagnosis and early treatment, and evaluate the effect of fecal protein dual-index detection reagents in early screening of colorectal cancer, so as to provide a scientific basis for optimizing the national screening program.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 74 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Subjects aged 45-74 years at time of consent
2. Have not had gastrointestinal resection

Exclusion Criteria:

1. Previous history of colorectal cancer
2. Patients who have been confirmed to have other malignant neoplastic diseases of the digestive system
3. Patients with severe heart, brain, lung disease or liver and kidney dysfunction or insufficiency
4. Those with severe mental disorders and language communication disorders
5. History of contraindications to colonoscopy
6. Pregnant women
```

## Primary Outcomes

- **Sensitivity of colorectal cancer detection** _(time frame: 180 days)_ — Sensitivity of colorectal cancer detection
- **Specificity of advanced neoplasia detection** _(time frame: 180 days)_ — Specificity of advanced neoplasia detection

## Secondary Outcomes

- **Positive predictive value of colorectal cancer detection** _(time frame: 180 days)_
- **Negative predictive value of colorectal cancer detection** _(time frame: 180 days)_
- **Sensitivity and specificity of advanced adenoma detection** _(time frame: 180 days)_

## Locations (1)

- The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China

## Recent Field Changes (last 30 days)

- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the first affiliated hospital of xinxiang medical university|xinxiang|henan|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06785714.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06785714*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*